Bumper Offer - Urjas oil Just @ Rs. 1
Olet 1.25 Tablet is a commercial drug that is prescribed in the form of Tablet. Schizophrenia are some of its major therapeutic uses. Other than this, Olet 1.25 Tablet has some other therapeutic uses, which have been discussed ahead.
The correct dosage of Olet 1.25 Tablet depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Some other side effects of Olet 1.25 Tablet have been listed ahead. Normally, these side effects of Olet 1.25 Tablet are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
Furthermore, you should know that effect of Olet 1.25 Tablet is Moderate for pregnant women and Severe for women who are breastfeeding. Further, the section on Olet 1.25 Tablet related warnings talks about Olet 1.25 Tablet's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Tardive Dyskinesia, Depression must refrain from the use of Olet 1.25 Tablet since this can cause severe adverse effects. The section on Olet 1.25 Tablet contraindications lists all such conditions.
Drug reaction of Olet 1.25 Tablet with other medicines has been reported. See below for a complete list.
In addition to the above precautions for Olet 1.25 Tablet, it is important to know that it is not safe while driving, and is not habit-forming.
Olet 1.25 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
Based on research, the following side effects have been observed when Olet 1.25 Tablet is used -
Moderate
Mild
Is the use of Olet 1.25 Tablet safe for pregnant women?
Olet (Alteus) can cause unwanted side effects in pregnant women. If you experience any side effects, stop taking Olet (Alteus) right away. Take your doctor's advice before taking it again.
Is the use of Olet 1.25 Tablet safe during breastfeeding?
Olet (Alteus) should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Olet 1.25 Tablet on the Kidneys?
Olet (Alteus) is completely safe for kidneys.
What is the effect of Olet 1.25 Tablet on the Liver?
Very few cases of side effects of Olet (Alteus) on the liver have been reported.
What is the effect of Olet 1.25 Tablet on the Heart?
Olet (Alteus) is rarely harmful for the heart.
Olet 1.25 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Olet 1.25 Tablet unless your doctor advises you to do so -
Is this Olet 1.25 Tablet habit forming or addictive?
Olet 1.25 Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
No, you should do not do anything that requires concentration and attention as the Olet 1.25 Tablet can make you feel drowsy.
Is it safe?
Olet 1.25 Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
Yes, in many cases, taking Olet 1.25 Tablet can help with mental disorders.
Interaction between Food and Olet 1.25 Tablet
When consumed with certain foods, Olet 1.25 Tablet may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Olet 1.25 Tablet
Consuming Olet 1.25 Tablet with alcohol can have many serious effects on your body.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 932-934
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 442
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa (olanzapine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa Intramuscular (olanzapine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa Relprevv (olanzapine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 932-934
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 442
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa (olanzapine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa Intramuscular (olanzapine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zyprexa Relprevv (olanzapine)
